NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 AMD
Advanced Micro Devices
-- 125.370 CRNC
Cerence
-- 19.330 PLTR
Palantir
-- 79.890 
NEWS
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Rallybio announced the publication of a manuscript detailing target-mediated drug disposition (TMDD) modeling used to determine RLYB212 dosing for pregnant women.
Rallybio announced the publication of a manuscript detailing target-mediated drug disposition (TMDD) modeling used to determine RLYB212 dosing for pregnant women.
The model incorporates pregnancy-related physiological changes and will be evaluated in their recently initiated Phase 2 clinical trial. RLYB212 is being developed to prevent alloimmunization in pregnant women and eliminate FNAIT risk in fetuses and newborns. The company is also conducting a natural history study, which has screened over 13,000 pregnant women as of November 1, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment